Related Experiment Video
Updated: Oct 2, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Dyslipidemia and its management after renal transplantation
1Department of Medicine Hennepin County Medical Center, Minneapolis, MN 55415, USA.
Abstract:
Dyslipidemias are common after renal transplantation. Most common are elevations in total and low-density lipoprotein cholesterol. Causes of dyslipidemia are usually multiple, but include immunosuppression (especially prednisone, cyclosporine and sirolimus), graft dysfunction (reduced glomerular filtration rate and proteinuria), and genetic predisposition. There is a growing amount of evidence suggesting that dyslipidemias contribute to the very high incidence of cardiovascular disease after transplantation. Less well established is whether the associations between dyslipidemias and graft dysfunction are due to a causal role of lipid abnormalities on renal injury. In any case, hypercholesterolemia, and especially increases in low density lipoprotein cholesterol, should be treated using guidelines established for patients in the general population.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Nephrotic Syndrome II : Assessment and Medical Management
Kidney Transplant III: Nursing Management
Atherosclerosis III: Management
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease II: Clinical Manifestations